SE9902937D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SE9902937D0
SE9902937D0 SE9902937A SE9902937A SE9902937D0 SE 9902937 D0 SE9902937 D0 SE 9902937D0 SE 9902937 A SE9902937 A SE 9902937A SE 9902937 A SE9902937 A SE 9902937A SE 9902937 D0 SE9902937 D0 SE 9902937D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical compositions
active ingredient
propylsulphonyl
phenylethoxy
benzothiazol
Prior art date
Application number
SE9902937A
Other languages
English (en)
Inventor
John Dixon
Philip Holt
Francis Ince
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9902937A priority Critical patent/SE9902937D0/sv
Publication of SE9902937D0 publication Critical patent/SE9902937D0/sv
Priority to PCT/GB2000/003114 priority patent/WO2001011933A2/en
Priority to AU64602/00A priority patent/AU6460200A/en
Priority to ARP000104311A priority patent/AR025341A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
SE9902937A 1999-08-18 1999-08-18 Pharmaceutical compositions SE9902937D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9902937A SE9902937D0 (sv) 1999-08-18 1999-08-18 Pharmaceutical compositions
PCT/GB2000/003114 WO2001011933A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor
AU64602/00A AU6460200A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions
ARP000104311A AR025341A1 (es) 1999-08-18 2000-08-18 Composiciones farmaceuticas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9902937A SE9902937D0 (sv) 1999-08-18 1999-08-18 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SE9902937D0 true SE9902937D0 (sv) 1999-08-18

Family

ID=20416695

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9902937A SE9902937D0 (sv) 1999-08-18 1999-08-18 Pharmaceutical compositions

Country Status (4)

Country Link
AR (1) AR025341A1 (sv)
AU (1) AU6460200A (sv)
SE (1) SE9902937D0 (sv)
WO (1) WO2001011933A2 (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
EP1685118B1 (en) 2003-11-21 2009-07-08 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
CA2714512A1 (en) * 2008-02-07 2009-08-13 The Children's Hospital Of Philadelphia Compositions and methods which modulate g-protein signaling for the treatment of asthma
US8569229B2 (en) 2008-02-07 2013-10-29 The Children's Hospital Of Philadelphia Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
AU2009260899B2 (en) 2008-06-18 2012-02-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211172D0 (en) * 1992-05-27 1992-07-08 Fisons Plc Compounds

Also Published As

Publication number Publication date
WO2001011933A2 (en) 2001-02-22
AU6460200A (en) 2001-03-13
AR025341A1 (es) 2002-11-20
WO2001011933A3 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
NO20034612L (no) 3,4-di-substituerte syklobuten-1,2-dioner, farmasoytiske preparater som omfatter forbindelsene, samt anvendelse av forbindelsene for tilvirkning av medikamenter for behandling av kjemokinformidlede sykdommer
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
FR2830447B1 (fr) Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
ATE248837T1 (de) Chinuclidin-acrylamide
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
SE9902935D0 (sv) Pharmaceutical compositions
HUP0400553A2 (hu) Gyógyászati készítmények
SE9902937D0 (sv) Pharmaceutical compositions
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
HUP0204511A2 (en) Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas
SE9903995D0 (sv) New combination
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
SE9902936D0 (sv) Pharmaceutical compositions
SE9902938D0 (sv) Pharmaceutical compositions
SE0001916D0 (sv) Novel formulation
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
WO2004018044A3 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
HUP0402092A2 (hu) 2-[5-(4-Fluorfenil)-3-piridilmetilaminometil]-kromán vegyületek és fiziológiásan elfogadható sói alkalmazása gyógyszerkészítmények előállítására
HUP0500078A2 (hu) PDE inhibitort és leukotrién antagonistát tartalmazó kombinált gyógyszerkészítmény